Sugi Predict

Sugi Predict / Compounds / SCHEMBL29988780

SCHEMBL29988780

SCHEMBL29988780

CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(=O)O)[C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 9/20 0.44
▸ CTSD P07339 3/20 0.44
▸ FOLH1 Q04609 1/20 0.43
▸ VIPR2 P41587 1/20 0.42
▸ BACE2 Q9Y5Z0 1/20 0.42
▸ NPY4R P50391 3/20 0.42
▸ NPY1R P25929 2/20 0.42
▸ NPY2R P49146 2/20 0.42
▸ NPY5R Q15761 2/20 0.42
▸ IL23R Q5VWK5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30228650 1.00 BACE1 (0.44) BACE1CTSDFOLH1VIPR2BACE2
SCHEMBL30228743 0.98 NPY4R (0.44) BACE1CTSDFOLH1VIPR2NPY4R
SCHEMBL30466504 0.94 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5R
SCHEMBL30942637 0.93 FOLH1 (0.43) FOLH1VIPR2IL23R
SCHEMBL31674373 0.93 NPY4R (0.44) BACE1CTSDFOLH1BACE2NPY4R
SCHEMBL31031482 0.92 NPY4R (0.51) BACE1CTSDBACE2NPY4RNPY1R
SCHEMBL31097750 0.91 NPY4R (0.52) VIPR2NPY4RNPY1RNPY2RNPY5R
SCHEMBL31344449 0.91 NPY4R (0.52) VIPR2NPY4RNPY1RNPY2RNPY5R
SCHEMBL29536365 0.91 NPY4R (0.49) NPY4RNPY1RNPY2RNPY5R
SCHEMBL29506967 0.91 NPY4R (0.49) NPY4RNPY1RNPY2RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180999-A1 EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING POST COVID-19 PANTAPHARM AG (DE) 2024-06-06 — — US claimed
EP-4313108-A1 EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING POST COVID-19 Pantapharm AG (DE) 2024-02-07 — — EP claimed
EP-4125996-A2 EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING COVID-19 Pantapharm AG (DE) 2023-02-08 — — EP claimed
WO-2022207818-A1 EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING POST COVID-19 PANTAPHARM AG (DE) 2022-10-06 — — WO claimed
US-20240180999-A1 EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING POST COVID-19 PANTAPHARM AG (DE) 2024-06-06 — — US disclosed
EP-4313108-A1 EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING POST COVID-19 Pantapharm AG (DE) 2024-02-07 — — EP disclosed
EP-4125996-A2 EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING COVID-19 Pantapharm AG (DE) 2023-02-08 — — EP disclosed
WO-2022207818-A1 EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING POST COVID-19 PANTAPHARM AG (DE) 2022-10-06 — — WO disclosed